What Is PT-141? Dosage, Half-Life & How to Track It

What PT-141 is and how it works

PT-141 is a synthetic cyclic peptide that is actually an active metabolite of Melanotan II — it’s what your body produces when it breaks MT-II down, and researchers isolated it as a more targeted follow-on compound. It works as a non-selective agonist at melanocortin receptors, mainly MC3R and MC4R, which sit in brain regions tied to reward and arousal (the nucleus accumbens and medial preoptic area) and increase dopamine release there.

That central mechanism is the whole reason it’s different from PDE5 inhibitors like sildenafil or tadalafil. Those work on vascular blood flow to the genitals; PT-141 works upstream, on desire itself, which is why the FDA approved it specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women — a desire problem, not a mechanical one. It’s also used off-label by men, sometimes alongside a PDE5 inhibitor.

Because it shares the MC1R-activating side of Melanotan II’s mechanism to some degree, mild skin darkening has been reported at higher or more frequent doses, though it is far less pronounced than with MT-II itself.

Typical dosing & reconstitution

The FDA-approved on-demand regimen is 1.75 mg subcutaneously, taken roughly 45 minutes before anticipated sexual activity, with a hard cap of 8 doses per month. Separately, daily titrated protocols exist in the research-peptide community, typically starting around 500 mcg and stepping up toward 1,000–1,500 mcg over several weeks — a different use pattern than the FDA on-demand dose, run by people using it more like a routine rather than an as-needed compound.

PT-141 comes as a lyophilized powder:

At 3.33 mg/mL, the 1.75 mg on-demand dose works out to about 52–53 units — drawn with a 1 mL syringe rather than a standard U-100. A 500 mcg titration dose is 15 units.

Half-life & what it means for frequency

PT-141’s half-life is around 2.7 hours, considerably longer than most reconstituted peptides but still short enough that its effects are meant to line up with a single occasion rather than persist for days. That is consistent with its FDA-approved use: taken roughly 45 minutes ahead of time, with effects that fade over the following hours.

The subcutaneous route matters here too — it gives close to full bioavailability and is better tolerated than the intranasal delivery explored in earlier trials, part of why the approved product is an injectable auto-injector rather than a spray.

What to track & common side effects

The most common side effects — reported in a large share of users at the on-demand dose — are nausea, flushing, and headache, along with injection-site reactions. Vyleesi’s label also carries a caution about a transient rise in blood pressure, which is why it’s not recommended for people with uncontrolled hypertension or cardiovascular disease, and why blood pressure is worth having checked before starting it.

What’s worth tracking: dose and timing relative to activity (useful both for effectiveness and for staying under the 8-dose-a-month cap), and any side effects — nausea in particular is common enough that many people track whether it fades with repeated use, which it often does.

Frequently asked questions